The patient management in advanced melanoma, breast and bladder cancers, in which PD-L1 antibodies have shown therapeutic efficacy but lack better response prediction and monitoring strategies, may particularly benefit from non-invasive PD-L1 detection at all the tumor sites. The gene discussed is CD274; the disease is neoplasm.